Nutraplus India (BOM:524764) Cyclically Adjusted Revenue per Share: ₹0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nutraplus India Cyclically Adjusted Revenue per Share?

Nutraplus India BOM:524764 Cyclically Adjusted Revenue per Share is ₹0.00 as of Mar. 2026. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Nutraplus India's adjusted revenue per share for the three months ended in Mar. 2026 was ₹0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹0.00 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-21), Nutraplus India's current stock price is ₹2.10. Nutraplus India's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹0.00. Nutraplus India's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nutraplus India was 0.06. The lowest was 0.04. And the median was 0.05.


Nutraplus India  (BOM:524764) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nutraplus India was 0.06. The lowest was 0.04. And the median was 0.05.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Nutraplus India Cyclically Adjusted Revenue per Share Related Terms


Nutraplus India Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Nutraplus India's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nutraplus India Cyclically Adjusted Revenue per Share Chart

Nutraplus India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nutraplus India Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BOM:524764 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nutraplus India's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nutraplus India Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nutraplus India's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nutraplus India's Cyclically Adjusted PS Ratio falls into.



Nutraplus India Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nutraplus India's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/164.2724*164.2724
=0.000

Current CPI (Mar. 2026) = 164.2724.

Nutraplus India Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 9.077 102.518 14.545
201606 8.742 105.961 13.553
201609 10.775 105.961 16.705
201612 7.202 105.196 11.247
201703 7.768 105.196 12.130
201706 4.680 107.109 7.178
201709 6.612 109.021 9.963
201712 9.421 109.404 14.146
201803 10.316 109.786 15.436
201806 8.009 111.317 11.819
201809 9.444 115.142 13.474
201812 12.615 115.142 17.998
201903 11.290 118.202 15.690
201906 8.963 120.880 12.180
201909 14.316 123.175 19.093
201912 6.422 126.235 8.357
202003 4.036 124.705 5.317
202006 0.003 127.000 0.004
202009 0.000 130.118 0.000
202012 0.000 130.889 0.000
202103 0.003 131.771 0.004
202106 0.016 134.084 0.020
202109 0.014 135.847 0.017
202112 0.000 138.161 0.000
202203 0.000 138.822 0.000
202206 0.000 142.347 0.000
202209 0.000 144.661 0.000
202212 0.000 145.763 0.000
202303 0.000 146.865 0.000
202306 0.000 150.280 0.000
202312 0.000 152.924 0.000
202403 0.000 153.035 0.000
202406 0.000 155.789 0.000
202409 0.000 157.882 0.000
202412 0.000 158.323 0.000
202503 0.000 157.552 0.000
202506 0.000 159.755 0.000
202509 0.000 162.289 0.000
202512 0.000 163.281 0.000
202603 0.000 164.272 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹0.00 mean?
Nutraplus India (BOM:524764) has a Cyclically Adjusted Revenue per Share of ₹0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nutraplus India and its competitors.
Is Nutraplus India's Cyclically Adjusted Revenue per Share too high?
Nutraplus India's current Cyclically Adjusted Revenue per Share is ₹0.00.
How does Nutraplus India's Cyclically Adjusted Revenue per Share compare to ZTS?
Nutraplus India's Cyclically Adjusted Revenue per Share of ₹0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nutraplus India and its competitors. Nutraplus India's current Cyclically Adjusted Revenue per Share is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nutraplus India stock overvalued right now?
Nutraplus India (BOM:524764) has a current Cyclically Adjusted Revenue per Share of ₹0.00. The current Cyclically Adjusted Revenue per Share is ₹0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Nutraplus India (BOM:524764), the current Cyclically Adjusted Revenue per Share is ₹0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nutraplus India Business Description

Address Subhash Road, 326-A, Pioneer Industrial Estate, Pioneer Eyelets Mfg. Co. Ltd., Jogeshwari (East), Mumbai, MH, IND, 400060
Nutraplus India Ltd is an India based company engaged in manufacturing of active pharmaceutical ingredients (API), intermediates and contract manufacturing of intermediates. It produces bulk drugs, and specialty chemicals and intermediates. The company's product portfolio encompasses therapeutic categories like analgesic, anti-asthma, antimalarial, anti-protozoan infections, mucolyting agent, and antihelmintic.